BioNano Genomics Inc vs Eaton Corporation plc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Eaton Corporation plc trades at $416.94 (market cap $161.35B). The key difference: Eaton Corporation plc is far larger — about 12223.5× BioNano Genomics Inc's market cap, and Eaton Corporation plc pays a 1.06% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | ETN | |
|---|---|---|
Market Cap | $13.20M | $161.35B |
Sector | Health | Technology |
52-Week High | $4.92 | $435.78 |
52-Week Low | $1.09 | $315.82 |
Enterprise Value | $15.81M | $182.43B |
Dividend Yield | — | 1.06% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Eaton Corporation (ETN) trades at $402.85, down 1.09% on the day, with a bearish technical signal from moving averages. The stock exhibits strong fundamentals, including a 13.99% net income margin and consistent quarterly earnings beats, most recently in Q1 2026. Recent news highlights growth in data center and aerospace markets, supported by strategic acquisitions and a $2.1 billion R&D investment in 2025.
The outlook remains positive, driven by robust analyst sentiment with a $449.50 consensus price target and no sell ratings. Key opportunities include exposure to high-growth infrastructure and AI-related power demand. Risks involve elevated valuation multiples, such as a P/E of 40.66, and potential execution challenges from recent investments, with Q2 2026 earnings on July 31, 2026, serving as a near-term catalyst.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →